Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
AssigneeThe U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsMasaru Kanekiyo, Julia Lederhofer, Yaroslav Tsybovsky, Sarah F. Andrews
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies are antigen binding fragments are disclosed that specifically bind to the underside of influenza A neuraminidase (NA). In some aspects, these antibodies and antigen binding fragments are used for in methods of treating a subject with an influenza A infection, such as an H3N2 infection. In more aspects, these antibodies and antigen binding fragments and bispecific antibodies for detection of an influenza virus in a sample, and for selecting vaccines.
Claims29
An isolated monoclonal antibody or antigen binding fragment thereof, comprising:
- a heavy chain variable region (VH) and a light chain variable region (VL) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 and a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, wherein the VH and VL are set forth as one of:
- a) SEQ ID NOs:
- 1 and 5, respectively (NDS.1);
- b) SEQ ID NOs:
- 17 and 21, respectively (NDS.3);
- c) SEQ ID NOs:
- 9 and 13, respectively (NDS.1.1);
- d) SEQ ID NOs:
- 25 and 29, respectively (NDS.1.2);
- e) SEQ ID NOs:
- 33 and 37, respectively (NDS.6);
- f) SEQ ID NOs:
- 41 and 45, respectively (NDS.8);
- g) SEQ ID NOs:
- 49 and 53, respectively (NDS.5);
- or
- h) SEQ ID NOs:
- 57 and 61, respectively (NDS.7);
- wherein the monoclonal antibody specifically binds to influenza A neuraminidase (NA) protein and inhibits an N2 influenza A virus.
(canceled)
25-26. (canceled)
(canceled)
30-34. (canceled)
Dependencies are inferred from the claim text.